Information Provided By: 
Fly News Breaks for August 24, 2015
BMY
Aug 24, 2015 | 07:08 EDT
Piper Jaffray analyst Richard Purkiss upgraded Bristol-Myers to Neutral from Underweight as he now views the stock as fairly valued after its recent pullback. Bristol-Myers continues to have strong R&D execution, particularly in immuno-oncology, but he believes that is priced into the stock trading near his $61 per share target, Purkiss tells investors in a research note. Bristol-Myers shares, which are down about 10.5% over the last month, closed Friday at $61.08.
News For BMY From the Last 2 Days
There are no results for your query BMY
